Job ID 2018_05: Postdoctoral Research Associate
Date Posted: October 25, 2018
​
Company Summary:
Adecto Pharmaceuticals is an early-stage cancer therapeutics company focused on developing an antibody-based targeted therapy against cancers that express the cell surface protein ADAM8. The ADAM8 protein is a critical driver of tumor growth and spread and has been implicated in a number of aggressive cancers including breast, liver, gastric, lung and pancreatic. Our initial focus is on triple-negative breast cancer but we plan on expanding to other oncology indications in the future. Adecto's technology is based on the discovery that two distinct extracellular portions of ADAM8 drive its multiple cancer promoting functions and must therefore be both inactivated for an effective therapeutic response. Using a proprietary method, Adecto has generated highly specific dual antagonist monoclonal anti-ADAM8 antibodies that simultaneously inhibit these two domains. Our top two dual inhibitors, termed ADPs, are currently advancing through preclinical development. Adecto’s mission is to bring this new therapy to patients with ADAM8-positive disease to help them live longer, healthy lives.
Role / Responsibilities:
Adecto Pharmaceuticals is currently seeking an outstanding postdoctoral research associate to join its growing team. The full-time role will utilize mouse models of breast cancer, and cell-based and molecular assays to study the mechanisms of ADP action either as monotherapies or in combination with various standard-of-care treatments or other experimental therapies. The successful candidate will directly contribute to the development of a new therapy with a potential to have high impact on patient lives. This position will be located in Boston, MA.
Required qualifications:
